Table 3.
Microbiology and antimicrobial therapy by treatment group
| Standard care n=138 | Rapid test-and-treat n=134 | Placebo n=137 | Lactobacillus reuteri probiotic n=135 | |
| Participants with treatable bacterial pathogens (Campylobacter, Shigella, enterotoxigenic Escherichia coli, enteropathogenic E. coli); n (%) | 82 (59.4) | 84 (62.7) | 84 (61.3) | 82 (60.7) |
| Participants with Cryptosporidium; n (%) | 4 (2.9) | 8 (6.0) | 5 (3.6) | 7 (5.2) |
| Participants documented as treated with cefotaxime; n (%) | 21 (15.6) | 21 (16.0) | 21 (15.7) | 21 (15.9) |
| Missing | 3 | 3 | 3 | 3 |
| Participants documented as treated with amoxicillin/clavulanic acid; n (%) | 7 (5.3) | 7 (5.3) | 9 (6.8) | 5 (3.8) |
| Missing | 6 | 3 | 5 | 4 |
| Participants documented as treated with nalidixic acid; n (%) | 8 (6.0) | 8 (6.1) | 11 (8.2) | 5 (3.8) |
| Missing | 4 | 3 | 3 | 4 |
| Participants documented as treated with gentamicin; n (%) | 28 (20.7) | 30 (22.7) | 31 (23.0) | 27 (20.5) |
| Missing | 3 | 2 | 2 | 3 |
| Participants documented as treated with azithromycin; n (%) | 0 | 69 (51.5) | 36 (26.3) | 33 (24.4) |
| Participants documented as treated with nitazoxanide; n (%) | 0 | 5 (3.7) | 2 (1.5) | 3 (2.2) |